Search

SARS-CoV-2 virus, which emerged in China and spread worldwide, caused the disease called COVID-19, and as a result, it was declared as a pandemic by the World Health Organization on March 11, 2020. SARS-CoV-2, a new virus for humans, has caused an increase in morbidity and mortality rates. Despite developments in vaccines and drugs, unfavorable effects of COVID-19 keep going. After the emergence of COVID-19, a disease that poses a great threat of morbidity and mortality, solutions have been searched to avoid from the virus and to overcome the disease after getting sick. As the importance of a strong immune system in the fight against infections is known, ways to strengthen immunity have been sought in addition to masks, distance and hygiene measures. For this reason, popularity of dietary supplements, which are thought to be effective on the immune system, has increased. Based on the positive studies on immunity and other viral infections in the literature, it is thought that dietary supplements can be useful against COVID-19. About dietary supplements on COVID-19, there are only a few randomized controlled studies, observational studies have been published mostly. In this review, the effects of dietary supplements on immunity, other viral infections and COVID-19 were examined.

Purpose:Endometrium cancers are the most common gynecological cancer type in women. Surgery is the standard treatment for women with early stage endometrial cancer patients. The adjuvant treatment of early stage endometrial cancer is based on the risk and expected type (local vs systemic) of relapse. In this study, we evaluated clinicopathological characteristics and treatment outcomes of endometrial cancer patients in our center.Materials and Methods:This study was a hospital-based retrospective observational case-series study. 116 patients were included in the study from Baskent University Department of Medical Oncology and Gynecological Oncology between the years of 2009-2015. De-novo metastatic patients were not included in the study. Results:The median age of the patients was 58 (range 27-81) years. All of patients had European Cooperative Oncology Group (ECOG) performance score 0 (n:116). Endometrioid histology was the most common histopathological subtype (n:103, 88%). All of the patients were in local and local advanced stage. The significant percentage of patients had grade 2 tumor (n:55, 47.4%). Myometrial invasion was less than 50% in 78 patients (67.2 %). The median follow-up time was 61 months and 8 (6.9%) patients died. All patients underwent standard surgical staging with standard lymphadenectomy. Overall survival (OS) was not reached. There were 14 patients (12.1 %) and 34 patients (29.3 %) treated with adjuvant chemotherapy and radiotherapy, respectively.Conclusion:Though endometrial cancer is the most common gynecological tumors in women, cure rate is very high. Relapse rate was 6 % (7 patients) and most of the relapse were local, 71.4% (5 patients).